← All candidates
One insider bought $20.0K in a single day.
33 filings on record.
TYRATyra Biosciences, Inc.
NasdaqGS · Healthcare · $1.52B
$25.43
+1.44% · Sep 15
One insider bought $20.0K in a single day.
Led by Verjee Rehan, director.
Price · 1Y · daily● 1 buy● 13 sells◆ 3 8-K
▸ hover a marker for the filing · drag to zoom · daily bars sharpen to 30-min on close ranges · 4 moves explained
AI brief · from the filings on this pagePro
The filings, the score and the setup on this page, read for you in about ten seconds — what the insiders did, and what stands against it.
Market cap
$1.52B
Float
35.3M
59% public
Short % float
Pro
The buyers
▸ each insider's past open-market buys, measured ~6 months (120 trading days) later, against the S&P over the same spans · split-adjusted · pre-scheduled 10b5-1 plan trades excluded · past outcomes, not predictions
10% owner
Ra Capital Management, L.p.
Bought $9.61M on Jun 4 — 997,864 sh @ $9.63, held indirect, 10% of their stake.
4 of 8 positions beat the S&P
Director
Verjee Rehan
Bought $20.0K on Sep 9 — 972 sh @ $20.58, held direct, 100% of their stake.
First Form 4 on file
The record
newest first
DateTypeInsiderOf stakeShares @ priceValue
21 more transactions on Pro →Context
Wall St
$49.40 avg target
+94.3% vs today · 10 analysts · consensus Strong Buy
▸ relayed analyst opinion, which tends to run optimistic — not our forecast or advice
Earnings · EPS vs forecast
2 of 5 quarters beat
Q2 '26−$0.69 act−$0.05
Q1 '26−$0.64 act−$0.05
Q4 '25−$0.57 act−$0.04
Q3 '25−$0.50 act+$0.01
Coverage
Is Tyra Biosciences, Inc. (TYRA) Stock a Biotech Opportunity Ahead of Key SURF302 Trial Data?Insider Monkey · 06-30Is Tyra Biosciences (TYRA) Too Reliant On Dabogratinib Amid Renewed SURF-302 Skepticism?Simply Wall St. · 06-12Tyra Biosciences' Weak Investor Sentiment Reflects Macro Pressures, Renewed SURF-302 Concerns, BofA SaysMT Newswires · 06-10Wolfe Research Initiates Peer Perform rating on Tyra Biosciences, Inc. (TYRA)Insider Monkey · 06-01
The file stays open
33 filings on record.
The next one will be too.
▸ SEC EDGAR · FINRA · Nasdaq — public sources only · research, not advice